Evotec (NASDAQ:EVO) Shares Up 10.8% on Better-Than-Expected Earnings

Evotec AG (NASDAQ:EVO) shares rose 10.8% during mid-day trading on Thursday following a better than expected earnings announcement. The stock traded as high as $1.6853 and last traded at $1.74. 127,378 shares were traded during trading, an increase of 26% from the average session volume of 101,035 shares. The stock had previously closed at $1.57.

The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.07. The firm had revenue of $186.81 million for the quarter, compared to analyst estimates of $165.34 million. Evotec had a negative return on equity of 24.93% and a negative net margin of 26.20%.

Trending Headlines about Evotec

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: Evotec reported Q3 revenue of €164.9 million and adjusted EBITDA loss of €1.6 million. Separately, analyst-reported figures showed a loss of $0.11 per share, narrower than the $0.18 consensus loss, and revenue of $186.81 million versus estimates of $165.34 million. D&PD base-business net sales rose 24%, pointing to stronger commercial momentum. Evotec Q3 and nine-month results
• Neutral Sentiment: Restructuring is moving forward, but its eventual effect on costs and growth will depend on execution. Nine-month adjusted EBITDA remained negative at €44.3 million, underscoring that the quarterly improvement has not yet resolved broader profitability challenges. Evotec narrows Q3 EBITDA loss
• Negative Sentiment: Evotec cut its 2030 revenue target and tempered and slightly postponed medium-term goals. The lower outlook may limit the impact of the quarterly beat by raising questions about the pace of recovery and long-term growth. Evotec cuts 2030 revenue target

Wall Street Analyst Weigh In

A number of brokerages have recently commented on EVO. Berenberg Bank lowered Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. Weiss Ratings downgraded shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 25th. TD Cowen lowered shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a research report on Wednesday, July 15th. Finally, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Evotec in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Evotec has a consensus rating of “Hold” and a consensus target price of $3.00.

Hedge Funds Weigh In On Evotec

Hedge funds have recently added to or reduced their stakes in the company. Optiver Holding B.V. boosted its position in Evotec by 598.4% during the first quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock worth $709,000 after purchasing an additional 242,973 shares during the period. WCM Investment Management LLC grew its holdings in Evotec by 12.1% during the first quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock valued at $1,480,000 after purchasing an additional 67,917 shares during the last quarter. Finally, Apollon Wealth Management LLC bought a new position in shares of Evotec in the first quarter valued at approximately $28,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

Evotec Stock Performance

The stock’s 50-day moving average price is $1.63 and its 200 day moving average price is $2.49. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.33 and a quick ratio of 2.21.

Evotec Company Profile

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec’s activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.